Onriva Trio

Indications

This medication is recommended for the long-term management of asthma in adults whose symptoms are not adequately controlled with a combination of a long-acting ß2-agonist and an inhaled corticosteroid. It aims to reduce asthma exacerbations.

Description

Our inhalation powder, Onriva Trio, delivers a unique combination of Indacaterol Acetate (an ultra-long-acting ß2-agonist), Glycopyrronium Bromide (an ultra-long-acting muscarinic antagonist), and Mometasone Furoate (an inhaled corticosteroid) directly to the lungs through oral inhalation.

Indacaterol: This ultra-long-acting ß2-agonist acts locally in the lungs to dilate bronchial passages, providing rapid and sustained bronchodilation.

Glycopyrronium: As an ultra-long-acting muscarinic antagonist, Glycopyrronium blocks the bronchoconstrictor effects of acetylcholine on airway smooth muscle, leading to widened airways.

Mometasone Furoate: A potent corticosteroid, Mometasone Furoate reduces inflammation by inhibiting the release of allergic mediators like leukotrienes from leukocytes.

Pharmacology

Indacaterol and Glycopyrronium work synergistically to relax bronchial smooth muscle, while Mometasone Furoate provides localized anti-inflammatory effects, collectively enhancing respiratory function.

Dosage & Administration

For oral inhalation only, Onriva Trio is administered once daily via an inhalation device. Patients should not exceed one inhalation capsule per day unless directed by a healthcare professional.

Interaction

Exercise caution when administering Onriva Trio alongside monoamine oxidase inhibitors, tricyclic antidepressants, or medications known to prolong the QT interval. Avoid concomitant use with ß2-adrenergic blockers.

Contraindications

Onriva Trio is contraindicated in individuals with hypersensitivity to any of its active substances or excipients.

Side Effects

Common adverse reactions observed over 52 weeks include nasopharyngitis, upper respiratory tract infections, and headaches.

Pregnancy & Lactation

Use during pregnancy or breastfeeding should be determined based on the potential benefit to the patient versus the potential risk to the fetus or infant.

Precautions & Warnings

Onriva Trio should not be used to treat acute asthma symptoms. Discontinue use immediately if allergic reactions like angioedema or urticaria occur. Monitor diabetic patients closely for changes in plasma glucose levels upon initiation of treatment.

Storage Conditions

Store below 30°C, protected from light and moisture, and out of reach of children. Only remove the capsule from its blister pack immediately before use with the inhalation device.